Cargando…
Role of Antifungal Combinations in Difficult to Treat Candida Infections
Candida infections are varied and, depending on the immune status of the patient, a life-threatening form may develop. C. albicans is the most prevalent species isolated, however, a significant shift towards other Candida species has been noted. Monotherapy is frequently indicated, but the patient’s...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468556/ https://www.ncbi.nlm.nih.gov/pubmed/34575770 http://dx.doi.org/10.3390/jof7090731 |
_version_ | 1784573700621729792 |
---|---|
author | Vitale, Roxana G. |
author_facet | Vitale, Roxana G. |
author_sort | Vitale, Roxana G. |
collection | PubMed |
description | Candida infections are varied and, depending on the immune status of the patient, a life-threatening form may develop. C. albicans is the most prevalent species isolated, however, a significant shift towards other Candida species has been noted. Monotherapy is frequently indicated, but the patient’s evolution is not always favorable. Drug combinations are a suitable option in specific situations. The aim of this review is to address this problem and to discuss the role of drug combinations in difficult to treat Candida infections. A search for eligible studies in PubMed and Google Scholar databases was performed. An analysis of the data was carried out to define in which cases a combination therapy is the most appropriate. Combination therapy may be used for refractory candidiasis, endocarditis, meningitis, eye infections and osteomyelitis, among others. The role of the drug combination would be to increase efficacy, reduce toxicity and improve the prognosis of the patient in infections that are difficult to treat. More clinical studies and reporting of cases in which drug combinations are used are needed in order to have more data that support the use of this therapeutic strategy. |
format | Online Article Text |
id | pubmed-8468556 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84685562021-09-27 Role of Antifungal Combinations in Difficult to Treat Candida Infections Vitale, Roxana G. J Fungi (Basel) Review Candida infections are varied and, depending on the immune status of the patient, a life-threatening form may develop. C. albicans is the most prevalent species isolated, however, a significant shift towards other Candida species has been noted. Monotherapy is frequently indicated, but the patient’s evolution is not always favorable. Drug combinations are a suitable option in specific situations. The aim of this review is to address this problem and to discuss the role of drug combinations in difficult to treat Candida infections. A search for eligible studies in PubMed and Google Scholar databases was performed. An analysis of the data was carried out to define in which cases a combination therapy is the most appropriate. Combination therapy may be used for refractory candidiasis, endocarditis, meningitis, eye infections and osteomyelitis, among others. The role of the drug combination would be to increase efficacy, reduce toxicity and improve the prognosis of the patient in infections that are difficult to treat. More clinical studies and reporting of cases in which drug combinations are used are needed in order to have more data that support the use of this therapeutic strategy. MDPI 2021-09-06 /pmc/articles/PMC8468556/ /pubmed/34575770 http://dx.doi.org/10.3390/jof7090731 Text en © 2021 by the author. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Vitale, Roxana G. Role of Antifungal Combinations in Difficult to Treat Candida Infections |
title | Role of Antifungal Combinations in Difficult to Treat Candida Infections |
title_full | Role of Antifungal Combinations in Difficult to Treat Candida Infections |
title_fullStr | Role of Antifungal Combinations in Difficult to Treat Candida Infections |
title_full_unstemmed | Role of Antifungal Combinations in Difficult to Treat Candida Infections |
title_short | Role of Antifungal Combinations in Difficult to Treat Candida Infections |
title_sort | role of antifungal combinations in difficult to treat candida infections |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468556/ https://www.ncbi.nlm.nih.gov/pubmed/34575770 http://dx.doi.org/10.3390/jof7090731 |
work_keys_str_mv | AT vitaleroxanag roleofantifungalcombinationsindifficulttotreatcandidainfections |